ACRS

Aclaris Therapeutics, Inc.

7 filings tracked

healthcarebiotechnologySMALL ($300M-2B)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

bullishMay 7

Raised $59.8 million through ATM offering to extend operational runway.

capital raise

70%

bearishMay 7

Net loss widened to $19.8 million for the quarter due to increased R&D spend.

earnings miss

60%

bearishMay 7

Operating expenses grew faster than licensing revenue, increasing the cash burn rate.

margin compression

50%

bullishMay 7

Raised $59.8 million through ATM offering to extend operational runway.

capital raise

70%

bearishMay 7

Net loss widened to $19.8 million for the quarter due to increased R&D spend.

earnings miss

60%

bearishMay 7

Operating expenses grew faster than licensing revenue, increasing the cash burn rate.

margin compression

50%

bullishMay 7

Raised $59.8 million through ATM offering to extend operational runway.

capital raise

70%

bearishMay 7

Net loss widened to $19.8 million for the quarter due to increased R&D spend.

earnings miss

60%

bearishMay 7

Operating expenses grew faster than licensing revenue, increasing the cash burn rate.

margin compression

50%

bullishMay 7

Raised $59.8 million through ATM offering to extend operational runway.

capital raise

70%

bearishMay 7

Net loss widened to $19.8 million for the quarter due to increased R&D spend.

earnings miss

60%

bearishMay 7

Operating expenses grew faster than licensing revenue, increasing the cash burn rate.

margin compression

50%

bullishMay 7

Raised $59.8 million through ATM offering to extend operational runway.

capital raise

70%

bearishMay 7

Net loss widened to $19.8 million for the quarter due to increased R&D spend.

earnings miss

60%

bearishMay 7

Operating expenses grew faster than licensing revenue, increasing the cash burn rate.

margin compression

50%

bullishMay 7

Raised $59.8 million through ATM offering to extend operational runway.

capital raise

70%

bearishMay 7

Net loss widened to $19.8 million for the quarter due to increased R&D spend.

earnings miss

60%

bearishMay 7

Operating expenses grew faster than licensing revenue, increasing the cash burn rate.

margin compression

50%

bullishMay 7

Raised $59.8 million through ATM offering to extend operational runway.

capital raise

70%

bearishMay 7

Net loss widened to $19.8 million for the quarter due to increased R&D spend.

earnings miss

60%

bearishMay 7

Operating expenses grew faster than licensing revenue, increasing the cash burn rate.

margin compression

50%

Filing History

10-QMay 7, 2026

The latest 10-Q reveals a company at a critical juncture, balancing high-risk clinical development with a sophisticated capital management strategy. Aclaris has successfully extended its runway through a $57.9 million ATM offering and the monetization of its Lilly royalties, providing a buffer that exceeds 12 months of operations. However, the increase in R&D spending to $15.7 million underscores the intensifying cost of advancing its pipeline toward pivotal data readouts. Investors are now weighing the potential of a multi-modal pipeline against the reality of sustained operating losses. The upcoming data for bosakitug in Q4 2026 and the Phase 1b results for ATI-052 in the second half of the year will likely serve as the primary determinants of the company's valuation. The central tension remains whether Aclaris can secure a transformative partnership before its current cash reserves are depleted by the escalating costs of late-stage clinical trials.